Theme: “Advanced Drug Design and Formulation Techniques to enhance Therapeutic Outcome”

Drug Formulation 2017

Drug Formulation 2017

Session/Tracks

Conference Series LLC  genially invites all the participants across the sphere to attend our prestigious conference “9th Annual Congress on Drug Formulation & Drug Design scheduled during October 19-21, 2017 Seoul, South Korea. Drug Formulation 2017 is an outstanding event which brings together a unique and International mix of large & medium Pharmaceutical industries/companies, leading top universities, research institutions building the conference a perfect podium to share their experience, foster collaborations across industry and academia, to evaluate emerging technologies across the globe.

 Track 1: Pre-formulation Studies

Pre-formulation is described as a phase of the research & development process where the pre-formulation scientist characterizes the Physico-chemical and mechanical properties of an Active Pharmaceutical ingredient, to develop stable, effective and safe dosage form. Formulation is a process in which several chemical substances, which includes the active drug, are mixed to produce a medicinal product. Pharmaceutical Formulation plays a very vital role in drug delivery to the desired target area in the body.  

Relevant Conferences:   

2nd Annual Global Drug Bioavailability Enhancement Summit January 24-25 , 2017 New York, USA; 3rd Annual Formulation & Drug Delivery Congress May 22 - 23, 2017, London, England; Drug Formualtion, Solubility & Bioavalibility Summit  March 27-29, 2017, Boston, USA; 4th Annual Congress on Drug Discovery & Designing July 03-05, 2017 Bangkok, Thailand; 16th Annual Medicinal & Pharmaceutical Sciences Congress July 03-05,2017, Kuala Lumpur, Malaysia; 11thInternational Conference on Pharmacoepidemiology and Clinical Research, July 06-08, 2017 Kuala Lumpur,Malaysia; 9th World Congress on BA/BE Studies and Biowaivers July 17-19, 2017 Melbourne, Australia; 14th International Conference and Exhibition on Pharmaceutical Formulations August 28-29, 2017 Brussels, Belgium; 11th World Drug Delivery Summit October 16-18, 2017, New York, USA

Related Associations or Societies:

Parenteral Drug Association(PDA); Bioanalytical Focus Group and Ligand Binding Assay; American Association of Pharmaceutical Scientists; Royal Netherlands Chemical Society; US Food and Drug Administration (FDA);  American Association for Clinical Chemistry (AACC); Generic Pharmaceutical Association; Canadian Generic Pharmaceutical Association (CGPA); Therapeutics Goods Administration (TGA); Clinical Trials Information from National Institutes for Health (NIH).

Track 2: Formulation

Formulation is the process where different chemical substances including the drug product which are combined to produce a medicinal product. There are various anatomical routes which are thought them as medical drugs that can be administered directly into the human body. The selection process of the route depends upon three factors which are: the effect desired type of disease & finally the type of product. Oral route is the oldest route which has been used for conventional & the novel drug delivery administration. Parenteral route, these are the routes which include intramuscular, intravenous, and intra-arterial and the subcutaneous route. Transdermal route is the medical treatment that will apply on surfaces of the body such as skin/mucous membrane. Inhalation route, is the type of medical treatment application route where the medical treatment will directly reach the lungs, through this way this route is considered as route of choice to avoid systemic effect and increase the bioavailability of the drug in the system.

Relevant Conferences:

2nd Annual Global Drug Bioavailability Enhancement Summit January 24-25 , 2017 New York, USA; 3rd Annual Formulation & Drug Delivery Congress May 22 - 23, 2017, London, England; Drug Formualtion, Solubility & Bioavalibility Summit  March 27-29, 2017, Boston, USA; 4th Annual Congress on Drug Discovery & Designing July 03-05, 2017 Bangkok, Thailand; 16th Annual Medicinal & Pharmaceutical Sciences Congress July 03-05,2017, Kuala Lumpur, Malaysia; 11thInternational Conference on Pharmacoepidemiology and Clinical Research, July 06-08, 2017 Kuala Lumpur,Malaysia; 9th World Congress on BA/BE Studies and Biowaivers July 17-19, 2017 Melbourne, Australia; 14th International Conference and Exhibition on Pharmaceutical Formulations August 28-29, 2017 Brussels, Belgium; 11th World Drug Delivery Summit October 16-18, 2017, New York, USA

Related Associations or Societies:

Parenteral Drug Association(PDA); Bioanalytical Focus Group and Ligand Binding Assay; American Association of Pharmaceutical Scientists; Royal Netherlands Chemical Society; US Food and Drug Administration (FDA);  American Association for Clinical Chemistry (AACC); Generic Pharmaceutical Association; Canadian Generic Pharmaceutical Association (CGPA); Therapeutics Goods Administration (TGA); Clinical Trials Information from National Institutes for Health (NIH).

Track 3: Drug Formulation Procedures

Drug Formulation Procedures will take a number of trials and screening at various stages so as to generate potent drug for the treatment of several diseases. After going through the different stages, the candidate found most suitable drug for the purpose is selected. systematic procedure is presented for selecting the carrier material and stabilizer for drug-loaded solid lipid micro particles. Formulation has become one of the most overlooked parts of drug development, but it can be the difference between an effective medicinal product and a very expensive placebo.

Relevant Conferences:

2nd Annual Global Drug Bioavailability Enhancement Summit January 24-25 , 2017 New York, USA; 3rd Annual Formulation & Drug Delivery Congress May 22 - 23, 2017, London, England; Drug Formualtion, Solubility & Bioavalibility Summit  March 27-29, 2017, Boston, USA; 4th Annual Congress on Drug Discovery & Designing July 03-05, 2017 Bangkok, Thailand; 16th Annual Medicinal & Pharmaceutical Sciences Congress July 03-05,2017, Kuala Lumpur, Malaysia; 11thInternational Conference on Pharmacoepidemiology and Clinical Research, July 06-08, 2017 Kuala Lumpur,Malaysia; 9th World Congress on BA/BE Studies and Biowaivers July 17-19, 2017 Melbourne, Australia; 14th International Conference and Exhibition on Pharmaceutical Formulations August 28-29, 2017 Brussels, Belgium; 11th World Drug Delivery Summit October 16-18, 2017, New York, USA

Related Associations or Societies:

Parenteral Drug Association(PDA); Bioanalytical Focus Group and Ligand Binding Assay; American Association of Pharmaceutical Scientists; Royal Netherlands Chemical Society; US Food and Drug Administration (FDA);  American Association for Clinical Chemistry (AACC); Generic Pharmaceutical Association; Canadian Generic Pharmaceutical Association (CGPA); Therapeutics Goods Administration (TGA); Clinical Trials Information from National Institutes for Health (NIH).

Track 4: Novel Drug Delivery System

The term drug delivery system was coined in the year 1970 to describe a series of technologies, used to develop finished drug products that were not immediate release. Drug release, absorption, distribution, and elimination process are to improve the product efficacy; safety, patient convenience and compliance are modified through drug delivery technologies. Oral route and parenteral route are the most common routes of drug delivery but in many conditions alternative drug delivery is favored. Drug delivery system is another term for formulation.

Relevant Conferences:

2nd Annual Global Drug Bioavailability Enhancement Summit January 24-25 , 2017 New York, USA; 3rd Annual Formulation & Drug Delivery Congress May 22 - 23, 2017, London, England; Drug Formualtion, Solubility & Bioavalibility Summit  March 27-29, 2017, Boston, USA; 4th Annual Congress on Drug Discovery & Designing July 03-05, 2017 Bangkok, Thailand; 16th Annual Medicinal & Pharmaceutical Sciences Congress July 03-05,2017, Kuala Lumpur, Malaysia; 11thInternational Conference on Pharmacoepidemiology and Clinical Research, July 06-08, 2017 Kuala Lumpur,Malaysia; 9th World Congress on BA/BE Studies and Biowaivers July 17-19, 2017 Melbourne, Australia; 14th International Conference and Exhibition on Pharmaceutical Formulations August 28-29, 2017 Brussels, Belgium; 11th World Drug Delivery Summit October 16-18, 2017, New York, USA

Related Associations or Societies:

Parenteral Drug Association(PDA); Bioanalytical Focus Group and Ligand Binding Assay; American Association of Pharmaceutical Scientists; Royal Netherlands Chemical Society; US Food and Drug Administration (FDA);  American Association for Clinical Chemistry (AACC); Generic Pharmaceutical Association; Canadian Generic Pharmaceutical Association (CGPA); Therapeutics Goods Administration (TGA); Clinical Trials Information from National Institutes for Health (NIH).

Track 5: Drug Evolution Process of IND, NDA & ANDA

Drug development is divided into types. The first type is Pre-clinical phase, usually takes 3 to 4 years to complete. If fruitful, this phase is followed by an appeal to the FDA as an Investigational New Drug (IND). After the approval by IND, the next stages are of clinical phases 1, 2, & 3, which require approximately 1-3 years for completion. Importantly, throughout the process of FDA, an investigator leading the clinical trials to communicate with each other so that safety is monitored. The manufacturer then files a New Drug Application (NDA) with the FDA for approval. This appeal can either be approved/ rejected; otherwise the Food and Drug Administration might request further study before making a quick decision. Following the acceptance, the FDA can also request the manufacturer to conduct additional post-marketing studies.  On average the entire process takes between 8 to 12 years.

Relevant Conferences:

2nd Annual Global Drug Bioavailability Enhancement Summit January 24-25 , 2017 New York, USA; 3rd Annual Formulation & Drug Delivery Congress May 22 - 23, 2017, London, England; Drug Formualtion, Solubility & Bioavalibility Summit  March 27-29, 2017, Boston, USA; 4th Annual Congress on Drug Discovery & Designing July 03-05, 2017 Bangkok, Thailand; 16th Annual Medicinal & Pharmaceutical Sciences Congress July 03-05,2017, Kuala Lumpur, Malaysia; 11thInternational Conference on Pharmacoepidemiology and Clinical Research, July 06-08, 2017 Kuala Lumpur,Malaysia; 9th World Congress on BA/BE Studies and Biowaivers July 17-19, 2017 Melbourne, Australia; 14th International Conference and Exhibition on Pharmaceutical Formulations August 28-29, 2017 Brussels, Belgium; 11th World Drug Delivery Summit October 16-18, 2017, New York, USA

Related Associations or Societies:

Parenteral Drug Association(PDA); Bioanalytical Focus Group and Ligand Binding Assay; American Association of Pharmaceutical Scientists; Royal Netherlands Chemical Society; US Food and Drug Administration (FDA);  American Association for Clinical Chemistry (AACC); Generic Pharmaceutical Association; Canadian Generic Pharmaceutical Association (CGPA); Therapeutics Goods Administration (TGA); Clinical Trials Information from National Institutes for Health (NIH).

Track 6: Role of API in Research & Development

Pharmaceutical research allows a rapid ramp-up of a diverse range of immediate and Novel Delivery Systems spanning Oral, Parenteral, Topical and Inhalation Dosage Forms. Our formulation expertise lies in the areas of taste masking, spray-drying, drug-layering, Nano-milling, lyophilisation and other pharmaceutical unit operations that enable us to cater to various formulation design needs and concepts. The ability to develop difficult-to-make, complex APIs by using the latest technologies is the key differentiating factor of our research. R&D productivity ranks among the highest for Indian generic companiesAnalytical Research and Development involves studies on APIs and other drugs, Stability study of APIs and formulations as per ICH guidelines, Pre-formulations study of APIs.

Relevant Conferences:

2nd Annual Global Drug Bioavailability Enhancement Summit January 24-25 , 2017 New York, USA; 3rd Annual Formulation & Drug Delivery Congress May 22 - 23, 2017, London, England; Drug Formualtion, Solubility & Bioavalibility Summit  March 27-29, 2017, Boston, USA; 4th Annual Congress on Drug Discovery & Designing July 03-05, 2017 Bangkok, Thailand; 16th Annual Medicinal & Pharmaceutical Sciences Congress July 03-05,2017, Kuala Lumpur, Malaysia; 11thInternational Conference on Pharmacoepidemiology and Clinical Research, July 06-08, 2017 Kuala Lumpur,Malaysia; 9th World Congress on BA/BE Studies and Biowaivers July 17-19, 2017 Melbourne, Australia; 14th International Conference and Exhibition on Pharmaceutical Formulations August 28-29, 2017 Brussels, Belgium; 11th World Drug Delivery Summit October 16-18, 2017, New York, USA

Related Associations or Societies:

Parenteral Drug Association(PDA); Bioanalytical Focus Group and Ligand Binding Assay; American Association of Pharmaceutical Scientists; Royal Netherlands Chemical Society; US Food and Drug Administration (FDA);  American Association for Clinical Chemistry (AACC); Generic Pharmaceutical Association; Canadian Generic Pharmaceutical Association (CGPA); Therapeutics Goods Administration (TGA); Clinical Trials Information from National Institutes for Health (NIH).

Track 6: Shelf Life & Stability Studies

It involves in developing the preparation of drug which is both stable and acceptable form to the patient which is essential for drug product marketing approval. Stability studies are conducted at all stages of the drug development cycle for different purposes with ultimate goal of having a stable product on the market.  During the development process of drug formulation stability studies are conducted to support formulation development, safety & efficacy claims of investigational new drugs.  At registration, they are conducted to ascertain the quality and also the shelf-life of drug product in their intended packaging configuration. After approval, stability studies are conducted to ensure the quality of production & to support site or other changes to the product.

Relevant conference:

2nd Annual Global Drug Bioavailability Enhancement Summit January 24-25 , 2017 New York, USA; 3rd Annual Formulation & Drug Delivery Congress May 22 - 23, 2017, London, England; Drug Formualtion, Solubility & Bioavalibility Summit  March 27-29, 2017, Boston, USA; 4th Annual Congress on Drug Discovery & Designing July 03-05, 2017 Bangkok, Thailand; 16th Annual Medicinal & Pharmaceutical Sciences Congress July 03-05,2017, Kuala Lumpur, Malaysia; 11thInternational Conference on Pharmacoepidemiology and Clinical Research, July 06-08, 2017 Kuala Lumpur,Malaysia; 9th World Congress on BA/BE Studies and Biowaivers July 17-19, 2017 Melbourne, Australia; 14th International Conference and Exhibition on Pharmaceutical Formulations August 28-29, 2017 Brussels, Belgium; 11th World Drug Delivery Summit October 16-18, 2017, New York, USA

Related Associations or Societies:

Parenteral Drug Association(PDA); Bioanalytical Focus Group and Ligand Binding Assay; American Association of Pharmaceutical Scientists; Royal Netherlands Chemical Society; US Food and Drug Administration (FDA);  American Association for Clinical Chemistry (AACC); Generic Pharmaceutical Association; Canadian Generic Pharmaceutical Association (CGPA); Therapeutics Goods Administration (TGA); Clinical Trials Information from National Institutes for Health (NIH).

Track 7: Drug Product Manufacturing         

Traditional and enhanced methods are not mutually exclusive. Today's competitive Pharmaceutical industry environment requires drug manufacturing that continuously strives to improve quality of the product while reducing production costs. So the drug product manufacturing track has been designed to focus on most advanced technology of manufacturing processes. The drug product manufacturing facility is designed to produce injectable biopharmaceuticals in syringes or vials in a Grade an environment. The fill and finish manufacturing line bulk frozen or liquid drug substance from own or other plants, which are thawed (if case frozen substance), prepared with the preservatives, buffering agents, pH adjusters, and filled into sterile nested vials or syringes being packed and shipped.

Relevant conference:

2nd Annual Global Drug Bioavailability Enhancement Summit January 24-25 , 2017 New York, USA; 3rd Annual Formulation & Drug Delivery Congress May 22 - 23, 2017, London, England; Drug Formualtion, Solubility & Bioavalibility Summit  March 27-29, 2017, Boston, USA; 4th Annual Congress on Drug Discovery & Designing July 03-05, 2017 Bangkok, Thailand; 16th Annual Medicinal & Pharmaceutical Sciences Congress July 03-05,2017, Kuala Lumpur, Malaysia; 11thInternational Conference on Pharmacoepidemiology and Clinical Research, July 06-08, 2017 Kuala Lumpur,Malaysia; 9th World Congress on BA/BE Studies and Biowaivers July 17-19, 2017 Melbourne, Australia; 14th International Conference and Exhibition on Pharmaceutical Formulations August 28-29, 2017 Brussels, Belgium; 11th World Drug Delivery Summit October 16-18, 2017, New York, USA

Related Associations or Societies:

Parenteral Drug Association(PDA); Bioanalytical Focus Group and Ligand Binding Assay; American Association of Pharmaceutical Scientists; Royal Netherlands Chemical Society; US Food and Drug Administration (FDA);  American Association for Clinical Chemistry (AACC); Generic Pharmaceutical Association; Canadian Generic Pharmaceutical Association (CGPA); Therapeutics Goods Administration (TGA); Clinical Trials Information from National Institutes for Health (NIH).

Track 8: Analytical Method Development and Validation

Analytical methods are validated to provide reliable data towards regulatory submissions. These methods are essential for several purposes, including testing of QC release, testing of stability samples, testing of reference materials and also to provide data towards support specifications. It provides a comprehensive coverage of method development & validation requirements to develop a pharmaceutical compound, at every stage of product development.Analytic method development, validation, and transfer are key elements of any pharmaceutical development program. This technical brief will focus on development and validation activities as applied to drug products.

Relevant conference:

2nd Annual Global Drug Bioavailability Enhancement Summit January 24-25 , 2017 New York, USA; 3rd Annual Formulation & Drug Delivery Congress May 22 - 23, 2017, London, England; Drug Formualtion, Solubility & Bioavalibility Summit  March 27-29, 2017, Boston, USA; 4th Annual Congress on Drug Discovery & Designing July 03-05, 2017 Bangkok, Thailand; 16th Annual Medicinal & Pharmaceutical Sciences Congress July 03-05,2017, Kuala Lumpur, Malaysia; 11thInternational Conference on Pharmacoepidemiology and Clinical Research, July 06-08, 2017 Kuala Lumpur,Malaysia; 9th World Congress on BA/BE Studies and Biowaivers July 17-19, 2017 Melbourne, Australia; 14th International Conference and Exhibition on Pharmaceutical Formulations August 28-29, 2017 Brussels, Belgium; 11th World Drug Delivery Summit October 16-18, 2017, New York, USA

Related Associations or Societies:

Parenteral Drug Association(PDA); Bioanalytical Focus Group and Ligand Binding Assay; American Association of Pharmaceutical Scientists; Royal Netherlands Chemical Society; US Food and Drug Administration (FDA);  American Association for Clinical Chemistry (AACC); Generic Pharmaceutical Association; Canadian Generic Pharmaceutical Association (CGPA); Therapeutics Goods Administration (TGA); Clinical Trials Information from National Institutes for Health (NIH).

Track 14: Medicinal Chemistry

Medicinal Chemistry is a branch of chemistry which especially deals with synthetic organic chemistry and pharmacology including various other biological specialties which is involved with design, chemical synthesis and development of drug for marketing of pharmaceutical agents.The Department of Medicinal Chemistry has always departed somewhat from this tradition given the focus of many of its faculty on the research areas of mechanistic drug metabolism, toxicology, and bioanalytical chemistry.

Relevant Conferences:

2nd Annual Global Drug Bioavailability Enhancement Summit January 24-25 , 2017 New York, USA; 3rd Annual Formulation & Drug Delivery Congress May 22 - 23, 2017, London, England; Drug Formualtion, Solubility & Bioavalibility Summit  March 27-29, 2017, Boston, USA; 4th Annual Congress on Drug Discovery & Designing July 03-05, 2017 Bangkok, Thailand; 16th Annual Medicinal & Pharmaceutical Sciences Congress July 03-05,2017, Kuala Lumpur, Malaysia; 11thInternational Conference on Pharmacoepidemiology and Clinical Research, July 06-08, 2017 Kuala Lumpur,Malaysia; 9th World Congress on BA/BE Studies and Biowaivers July 17-19, 2017 Melbourne, Australia; 14th International Conference and Exhibition on Pharmaceutical Formulations August 28-29, 2017 Brussels, Belgium; 11th World Drug Delivery Summit October 16-18, 2017, New York, USA

Related Associations or Societies:

Parenteral Drug Association(PDA); Bioanalytical Focus Group and Ligand Binding Assay; American Association of Pharmaceutical Scientists; Royal Netherlands Chemical Society; US Food and Drug Administration (FDA);  American Association for Clinical Chemistry (AACC); Generic Pharmaceutical Association; Canadian Generic Pharmaceutical Association (CGPA); Therapeutics Goods Administration (TGA); Clinical Trials Information from National Institutes for Health (NIH).

Track 15: Pharmacokinetics and Pharmacodynamics in Drugs

Pharmacokinetics is currently defined as the study of the time course of drug absorption, distribution, metabolism, and excretion. Clinical pharmacokinetics is the application of pharmacokinetic principles to the safe and effective therapeutic management of drugs in an individual patient. Primary goals of clinical pharmacokinetics include enhancing efficacy and decreasing toxicity of a patient’s drug therapy. The development of strong correlations between drug concentrations and their pharmacologic responses has enabled clinicians to apply pharmacokinetic principles to actual patient situations. Pharmacodynamics refers to the relationship between drug concentration at the site of action and the resulting effect, including the time course and intensity of therapeutic and adverse effects. The effect of a drug present at the site of action is determined by that drug’s binding with a receptor. Receptors may be present on neurons in the central nervous system (i.e., opiate receptors) to depress pain sensation, on cardiac muscle to affect the intensity of contraction, or even within bacteria to disrupt maintenance of the bacterial cell wall.

Relevant Conferences:

2nd Annual Global Drug Bioavailability Enhancement Summit January 24-25 , 2017 New York, USA; 3rd Annual Formulation & Drug Delivery Congress May 22 - 23, 2017, London, England; Drug Formualtion, Solubility & Bioavalibility Summit  March 27-29, 2017, Boston, USA; 4th Annual Congress on Drug Discovery & Designing July 03-05, 2017 Bangkok, Thailand; 16th Annual Medicinal & Pharmaceutical Sciences Congress July 03-05,2017, Kuala Lumpur, Malaysia; 11thInternational Conference on Pharmacoepidemiology and Clinical Research, July 06-08, 2017 Kuala Lumpur,Malaysia; 9th World Congress on BA/BE Studies and Biowaivers July 17-19, 2017 Melbourne, Australia; 14th International Conference and Exhibition on Pharmaceutical Formulations August 28-29, 2017 Brussels, Belgium; 11th World Drug Delivery Summit October 16-18, 2017, New York, USA

Related Associations or Societies:

Parenteral Drug Association(PDA); Bioanalytical Focus Group and Ligand Binding Assay; American Association of Pharmaceutical Scientists; Royal Netherlands Chemical Society; US Food and Drug Administration (FDA);  American Association for Clinical Chemistry (AACC); Generic Pharmaceutical Association; Canadian Generic Pharmaceutical Association (CGPA); Therapeutics Goods Administration (TGA); Clinical Trials Information from National Institutes for Health (NIH).

Track 16: Drug Targeting

The most fundamental goal in drug design is to predict whether a given molecule will bind to a target and if so how strongly. Molecular mechanics or molecular dynamics are most often used to predict the conformation of the small molecule and to model conformational changes in the biological target that may occur when the small molecule binds to it. The therapeutic response of a drug depends upon the interaction of drug molecules with cell on cell membrane related biological events at receptor sites in concentration dependent manner. Selective and effective localization of the pharmacologically-active moiety at pre-identified targets in therapeutic concentration, while restricting its access to non-target(s) normal cellular linings, thus minimizing toxic effects and maximizing the therapeutic index accounts from effective and efficient drug deliveryMolecular mechanics methods may also be used to provide semi-quantitative prediction of the binding affinity. Also, knowledge-based scoring function may be used to provide binding affinity estimates. These methods use linear regression, machine learning, neural nets or other statistical techniques to derive predictive binding affinity equations by fitting experimental affinities to computationally derived interaction energies between the small molecule and the target.

Relevant Conferences:

2nd Annual Global Drug Bioavailability Enhancement Summit January 24-25 , 2017 New York, USA; 3rd Annual Formulation & Drug Delivery Congress May 22 - 23, 2017, London, England; Drug Formualtion, Solubility & Bioavalibility Summit  March 27-29, 2017, Boston, USA; 4th Annual Congress on Drug Discovery & Designing July 03-05, 2017 Bangkok, Thailand; 16th Annual Medicinal & Pharmaceutical Sciences Congress July 03-05,2017, Kuala Lumpur, Malaysia; 11thInternational Conference on Pharmacoepidemiology and Clinical Research, July 06-08, 2017 Kuala Lumpur,Malaysia; 9th World Congress on BA/BE Studies and Biowaivers July 17-19, 2017 Melbourne, Australia; 14th International Conference and Exhibition on Pharmaceutical Formulations August 28-29, 2017 Brussels, Belgium; 11th World Drug Delivery Summit October 16-18, 2017, New York, USA

Related Associations or Societies:

Parenteral Drug Association(PDA); Bioanalytical Focus Group and Ligand Binding Assay; American Association of Pharmaceutical Scientists; Royal Netherlands Chemical Society; US Food and Drug Administration (FDA);  American Association for Clinical Chemistry (AACC); Generic Pharmaceutical Association; Canadian Generic Pharmaceutical Association (CGPA); Therapeutics Goods Administration (TGA); Clinical Trials Information from National Institutes for Health (NIH).

Track 17: Rational Drug Design

Rational Drug design or drug design is the technique of inventing innovative medications. Generally, the drug is a tiny organic molecule which triggers or slows down the activity of a bio-molecule such as a protein which consecutively results in a medicinal benefit to the patient. Discovery of effective drugs is challenging. Various medications are invented by chance observations, the scientific examination of other medicines or by finding out the side effects of some other drugs. A methodical technique is significant screening observations where important drug targets are tested with thousands of various compounds to observe, whether interactions occur. Basically, drug design involves design of small molecules that are harmonizing in shape and charge to the bio molecular target to which they act together and consequently will bind to it.

Relevant Conferences:

2nd Annual Global Drug Bioavailability Enhancement Summit January 24-25 , 2017 New York, USA; 3rd Annual Formulation & Drug Delivery Congress May 22 - 23, 2017, London, England; Drug Formualtion, Solubility & Bioavalibility Summit  March 27-29, 2017, Boston, USA; 4th Annual Congress on Drug Discovery & Designing July 03-05, 2017 Bangkok, Thailand; 16th Annual Medicinal & Pharmaceutical Sciences Congress July 03-05,2017, Kuala Lumpur, Malaysia; 11thInternational Conference on Pharmacoepidemiology and Clinical Research, July 06-08, 2017 Kuala Lumpur,Malaysia; 9th World Congress on BA/BE Studies and Biowaivers July 17-19, 2017 Melbourne, Australia; 14th International Conference and Exhibition on Pharmaceutical Formulations August 28-29, 2017 Brussels, Belgium; 11th World Drug Delivery Summit October 16-18, 2017, New York, USA

Related Associations or Societies:

Parenteral Drug Association(PDA); Bioanalytical Focus Group and Ligand Binding Assay; American Association of Pharmaceutical Scientists; Royal Netherlands Chemical Society; US Food and Drug Administration (FDA);  American Association for Clinical Chemistry (AACC); Generic Pharmaceutical Association; Canadian Generic Pharmaceutical Association (CGPA); Therapeutics Goods Administration (TGA); Clinical Trials Information from National Institutes for Health (NIH).

Track 18: Computer Aided Drug Designing (CADD)

Over the past decade, the drug discovery landscape has changed dramatically. Many pharmaceutical companies have shifted their research efforts from enzyme targets to programs based on more complex phenotypic screens. These screens create rich datasets, which often lack the resolution found in traditional enzyme assays. Even in cases where drug targets are known, teams must design compounds that are selective for the target of interest and avoid potential off-target liabilities. In addition, drug discovery programs often track dozens of assays, creating large volumes of data that must be analyzed and understood. Public repositories containing millions of chemical structures associated with tens of millions of biological activity values are now readily available. While this data could provide a benefit to on-going drug discovery programs, its use is currently limited.

Relevant Conferences:

2nd Annual Global Drug Bioavailability Enhancement Summit January 24-25 , 2017 New York, USA; 3rd Annual Formulation & Drug Delivery Congress May 22 - 23, 2017, London, England; Drug Formualtion, Solubility & Bioavalibility Summit  March 27-29, 2017, Boston, USA; 4th Annual Congress on Drug Discovery & Designing July 03-05, 2017 Bangkok, Thailand; 16th Annual Medicinal & Pharmaceutical Sciences Congress July 03-05,2017, Kuala Lumpur, Malaysia; 11thInternational Conference on Pharmacoepidemiology and Clinical Research, July 06-08, 2017 Kuala Lumpur,Malaysia; 9th World Congress on BA/BE Studies and Biowaivers July 17-19, 2017 Melbourne, Australia; 14th International Conference and Exhibition on Pharmaceutical Formulations August 28-29, 2017 Brussels, Belgium; 11th World Drug Delivery Summit October 16-18, 2017, New York, USA

Related Associations or Societies:

Parenteral Drug Association(PDA); Bioanalytical Focus Group and Ligand Binding Assay; American Association of Pharmaceutical Scientists; Royal Netherlands Chemical Society; US Food and Drug Administration (FDA);  American Association for Clinical Chemistry (AACC); Generic Pharmaceutical Association; Canadian Generic Pharmaceutical Association (CGPA); Therapeutics Goods Administration (TGA); Clinical Trials Information from National Institutes for Health (NIH).

Track 19: Bio Markers in Drug Designing

Biomarkers are key molecular or cellular events that link a specific environmental exposure to a health outcome. Biomarkers play an important role in understanding the relationships between exposure to environmental chemicals, the development of chronic human diseases, and the identification of subgroups that are at increased risk for disease. Much progress has been made in identifying and validating new biomarkers that can be used in population-based studies of environmental disease. There is interest in biomarker discovery on the part of the pharmaceutical industry; blood-test or other biomarkers could serve as intermediate markers of disease in clinical trials, and as possible drug targets.

Relevant Conferences:

2nd Annual Global Drug Bioavailability Enhancement Summit January 24-25 , 2017 New York, USA; 3rd Annual Formulation & Drug Delivery Congress May 22 - 23, 2017, London, England; Drug Formualtion, Solubility & Bioavalibility Summit  March 27-29, 2017, Boston, USA; 4th Annual Congress on Drug Discovery & Designing July 03-05, 2017 Bangkok, Thailand; 16th Annual Medicinal & Pharmaceutical Sciences Congress July 03-05,2017, Kuala Lumpur, Malaysia; 11thInternational Conference on Pharmacoepidemiology and Clinical Research, July 06-08, 2017 Kuala Lumpur,Malaysia; 9th World Congress on BA/BE Studies and Biowaivers July 17-19, 2017 Melbourne, Australia; 14th International Conference and Exhibition on Pharmaceutical Formulations August 28-29, 2017 Brussels, Belgium; 11th World Drug Delivery Summit October 16-18, 2017, New York, USA

Related Associations or Societies:

Parenteral Drug Association(PDA); Bioanalytical Focus Group and Ligand Binding Assay; American Association of Pharmaceutical Scientists; Royal Netherlands Chemical Society; US Food and Drug Administration (FDA);  American Association for Clinical Chemistry (AACC); Generic Pharmaceutical Association; Canadian Generic Pharmaceutical Association (CGPA); Therapeutics Goods Administration (TGA); Clinical Trials Information from National Institutes for Health (NIH).

Track 20: Clinical Studies

Clinical Trial and research studies which tests how well new medical approaches work in people. These studies gives answers for scientific questions and tries to find better ways to eradicate, screen, diagnose or treat a disease. Clinical trials  compares a new treatment to a treatment that already exists.

Relevant Conferences:

2nd Annual Global Drug Bioavailability Enhancement Summit January 24-25 , 2017 New York, USA; 3rd Annual Formulation & Drug Delivery Congress May 22 - 23, 2017, London, England; Drug Formualtion, Solubility & Bioavalibility Summit  March 27-29, 2017, Boston, USA; 4th Annual Congress on Drug Discovery & Designing July 03-05, 2017 Bangkok, Thailand; 16th Annual Medicinal & Pharmaceutical Sciences Congress July 03-05,2017, Kuala Lumpur, Malaysia; 11thInternational Conference on Pharmacoepidemiology and Clinical Research, July 06-08, 2017 Kuala Lumpur,Malaysia; 9th World Congress on BA/BE Studies and Biowaivers July 17-19, 2017 Melbourne, Australia; 14th International Conference and Exhibition on Pharmaceutical Formulations August 28-29, 2017 Brussels, Belgium; 11th World Drug Delivery Summit October 16-18, 2017, New York, USA

Related Associations or Societies:

Parenteral Drug Association(PDA); Bioanalytical Focus Group and Ligand Binding Assay; American Association of Pharmaceutical Scientists; Royal Netherlands Chemical Society; US Food and Drug Administration (FDA);  American Association for Clinical Chemistry (AACC); Generic Pharmaceutical Association; Canadian Generic Pharmaceutical Association (CGPA); Therapeutics Goods Administration (TGA); Clinical Trials Information from National Institutes for Health (NIH).

Track 21: Regulatory Requirements

Regulatory affairs are to protect public health by controlling the safety and efficacy of products in pharmaceutical sectors involves medicines and devices. Now a day the increase in the quality of attention in regulatory affairs has created enough challenges to satisfy the strain of health authorities and regulatory agencies. Merely keeping up on changes within the requisites of the markets we need a frenzied team of specialists. The roles and responsibilities typically begin within the analysis and development phases, going in clinical trials and lengthening through premarket approvals, producing, labelling, advertising and post market work best in both Biologics and biotechnology products.

Relevant Conferences:

2nd Annual Global Drug Bioavailability Enhancement Summit January 24-25 , 2017 New York, USA; 3rd Annual Formulation & Drug Delivery Congress May 22 - 23, 2017, London, England; Drug Formualtion, Solubility & Bioavalibility Summit  March 27-29, 2017, Boston, USA; 4th Annual Congress on Drug Discovery & Designing July 03-05, 2017 Bangkok, Thailand; 16th Annual Medicinal & Pharmaceutical Sciences Congress July 03-05,2017, Kuala Lumpur, Malaysia; 11thInternational Conference on Pharmacoepidemiology and Clinical Research, July 06-08, 2017 Kuala Lumpur,Malaysia; 9th World Congress on BA/BE Studies and Biowaivers July 17-19, 2017 Melbourne, Australia; 14th International Conference and Exhibition on Pharmaceutical Formulations August 28-29, 2017 Brussels, Belgium; 11th World Drug Delivery Summit October 16-18, 2017, New York, USA

Related Associations or Societies:

Parenteral Drug Association(PDA); Bioanalytical Focus Group and Ligand Binding Assay; American Association of Pharmaceutical Scientists; Royal Netherlands Chemical Society; US Food and Drug Administration (FDA);  American Association for Clinical Chemistry (AACC); Generic Pharmaceutical Association; Canadian Generic Pharmaceutical Association (CGPA); Therapeutics Goods Administration (TGA); Clinical Trials Information from National Institutes for Health (NIH).

 





About Conference

Conference Series LLC  is organizing international conference “9th Annual Congress on Drug Formulation & Drug Design scheduled during October 19-21, 2017 Seoul, South Korea.

Drug Formulation is a process in Pharmaceutical sciences. Formulation means compounding of single or mixture of active ingredients, excipients like Fillers, Disintegrants, Lubricants, Glidants, and Binders etc., are packed in a single pack to form a Pharmaceutical Drug. Formulation deals with Active Pharmaceutical Ingredient in Packaging of finished product which means Analytical R & D, Formulation R & D, Blending, Drying, Punching or Filling, Packaging. Formulations are of different dosage forms like Oral Dosage Forms, Parenteral Dosage Forms & topical dosage Forms. Pharmaceutical drug formulation is the development of a bioavailable, stable and optimal dosage form for a precise administration route.

In the light theme, the conference series aims to provide a forum for international researchers from various research areas of biomedical, Pharmaceutical, clinical sciences by providing a platform for critical analysis of new data & also to share the latest cutting-edge research findings and results about all aspects of Drug Formulation.  

Conference Highlights:

  • Pre-formulation Studies
  • Formulation
  • Drug Formulation Procedures
  • Novel Drug Delivery System
  • Drug Evolution Process of IND, NDA & ANDA
  • Role of API In Research & Development
  • Shelf Life & Stability Studies
  • Drug Product Manufacturing
  • Analytical Method Development and Validation
  • Medicinal Chemistry
  • Pharmacokinetics and Pharmacodynamics in Drugs
  • Drug Targeting
  • Rational Drug Design
  • Computer Aided Drug Designing (CADD)
  • Bio Markers in Drug Designing
  • Clinical Studies
  • Regulatory Requirements
  • Entrepreneur Investment




Market Analysis

Conference Series LLC  welcomes Students, Pharmaceutical companies / industries, leading universities and research institutions, presenters, and exhibitors from all over the world to Beijing, China. We are delighted to invite you all to attend and register for the 9th Annual Congress on Drug Formulation & Drug Design (Drug Formulation 2017) which is going to be held during October 19-21, 2017 Seoul, South Korea. We invite you to join us at the Drug Formulation 2016, where you will be sure to have a meaningful experience with scholars from around the world. All members of the Drug Formulation 2017 organizing committee look forward to meeting you in Seoul, South Korea.

Why Korea?

Global Pharmaceutical Industry in its operation and innovation activities is now facing serious challenges resulted by mega trends in healthcare paradigm. Korean R&D-based pharmaceutical companies have been involving in pioneering unmet medical needs areas investing over 65% to their annual net profit with the strong support from the Korean government. Modern pharmaceutical industry in Korea has 110 years of history initiating at the end of the 1800s, when a first modern pharmaceutical company began its operation.

  • Although with a comparatively small market size, US$ 16 billion in production occupying 1.5% of global market at present, Korean market is expected to grow up unceasingly with rapid annual growth rate of 10% in domestic market surpassing the world average 3-5%. To overcome the small market size in comparison with bigger market in US, EU etc., the Korean pharmaceutical industry has been accelerating their innovation activities in new drug R&D for early entering the overseas market.
  • According to the recent analysis data by Korea Health Industry Development Institute (KHIDI), major 46 R&D-Based Korean pharmaceutical companies recently designated to be innovative pharmaceutical companies by the Ministry of Health & Welfare of Korea will increase R&D investment from 1,272,300 KRW million to 3,879,800 KRW million by 2020.
  • As for the Korean pharmaceutical industry, during the past 30 years there has been marvellous advancement in new drug research and development; market-launched 33 new drugs approved by the Korean regulatory agency(MFDS), US-FDA approved 2 drugs, world's first monoclonal antibody bio-similar, around 15 IND-approved(by US FDA, EMA) new drug candidates, 200 or so out-licenced(to 30 countries) new drug candidates & technologies, 300 or so finished drugs & APIs already launched in overseas market including US and EU, 1,000 or so leads or druggable candidates existing in Korean pharmas' labs, 124 to be commercialized in the global market by 2014~2016 etc. Considering the success possibility, 31 of new drugs are expected by 2020.

Korean R&D-based pharmaceutical companies have been involving in pioneering unmet medical needs areas investing over 65% to their annual net profit with the strong support from the Korean government. Modern pharmaceutical industry in Korea has 110 years of history initiating at the end of the 1800s, when a first modern pharmaceutical company began its operation.

  • Korean market is expected to grow up unceasingly with rapid annual growth rate of 10% in domestic market surpassing the world average 3-5%. To overcome the small market size in comparison with bigger market in US, EU etc., the Korean pharmaceutical industry has been accelerating their innovation activities in new drug R&D for early entering the overseas market.
  • According to the recent analysis data by Korea Health Industry Development Institute (KHIDI), major 46 R&D-Based Korean pharmaceutical companies recently designated to be innovative pharmaceutical companies by the Ministry of Health & Welfare of Korea will increase R&D investment from 1,272,300 KRW million to 3,879,800 KRW million by 2020.
  • As for the Korean pharmaceutical industry, during the past 30 years there has been marvelous advancement in new drug research and development; market-launched 33 new drugs approved by the Korean regulatory agency(MFDS), US-FDA approved 2 drugs, world's first monoclonal antibody bio-similar, around 15 IND-approved(by US FDA, EMA) new drug candidates, 200 or so out-licenced(to 30 countries) new drug candidates & technologies, 300 or so finished drugs & APIs already launched in overseas market including US and EU, 1,000 or so leads or drug candidates existing in Korean pharmas' labs. Considering the success possibility, 31 of new drugs are expected by 2020.

Korean Pharmaceutical Industry owes these successful innovation activities and future vision to not only their own strong passion & resolute R&D investment for growth strategy through innovation in new drug research and development but also systemic R&D ecosystem surrounding the industry; optimized R&D environment closely linked to the industry and strong governmental support.

Accompanied by 150 or so universities and colleges having strong needs for R&D co-works and technology commercialization with the industry with their excellent IP assets in early stage research areas, 6 major public research institutes(Korea Institute of Science & Technology, Korea Research Institute of Bioscience & Biotechnology, Korea Research Institute of Chemical Technology, Korea Basic Science Institute, Institute Pasteur Korea, Korea Institute of Toxicology) having excellent research abilities in basic & applied science and superior research infrastructure and 19 preclinical trial organizations & 163 clinical trial facilities, most of the R&D based Korean pharmaceutical companies have been pioneering the future with new drug R&D.

Drug Formulation in Asia-Pacific:

Drug delivery refers to technologies, formulations/systems (based on drug vehicles/carriers) and approaches (route of administration) used to deliver drugs for various applications/therapeutic use.  Advanced drug delivery technologies refer to the technologies used for controlling the rate of drug release. The report focuses on modified drug delivery technologies such as extended release (controlled and sustained release), controlled release, targeted release, delayed release and pulsatile release.

  • The advanced drug delivery market is expected to increase from about $178.8 billion in 2015 to nearly $227.3 billion in 2020, reflecting a five-year compound annual growth rate (CAGR) of 4.9%. North America leads the global advanced drug delivery market, followed by Europe. However, Asia-Pacific should grow the fastest during the forecast period with a five-year CAGR of 6.4%.

Major associations around the globe:

  •  Parenteral Drug Association (PDA)
  •  Bioanalytical Focus Group and Ligand Binding Assay
  •  American Association of Pharmaceutical Scientists (AAPS)
  •  Royal Netherlands Chemical Society
  •  US Food and Drug Administration (FDA)
  •  American Association for Clinical Chemistry (AACC)
  •  American Association of Pharmaceutical Scientists (AAPS)
  •  Clinical Trials Information from National Institutes for Health (NIH)
  •  ORPHANET Parenteral Drug Association
  •  BEBAC Consultancy Services for Bioequivalence and Bioavailability
  •  European Generic medicines Association
  •  Therapeutics Goods Administration (TGA)




Past Conference Report

Drug Formulation 2016

Conference Series LLC hosted the Drug Formulation & Bioavailability Congress at Double Tree by Hillton, Beijing, China during September 05-07, 2016. The conference was designed around the theme of “Advanced Drug Formulation perspectives for Comprehensive Bioavailability” and was a great success where eminent keynote speakers from various reputed companies made their resplendent presence and addressed the gathering. Moreover, the networking sessions laid the foundation for some time worthy collaborations between many start-up and big industries. The post conference networking lunch session witnessed a number of B2B meetings that are turning up to be mutually beneficial to both the organizations who had gone in for the business meetings.

Drug Formulation 2016 witnessed an amalgamation of peerless speakers who enlightened the crowd with their knowledge and confabulated on various new-fangled topics related to the field of pharma. This congress not only brought forward the latest developments in the field but also provided solutions to the numerous challenges encountered in developing a drug.

Conference Series LLC would like to convey a warm gratitude to all the Honourable guests, Keynote Speakers, Delegates, Media Partners and Exhibitors for their participation in Drug Formulation 2016.

We on behalf of the conference specially thank the exhibitors for their participation in the congress and also the media partners for their wonderful marketing of the event. Conference Series LLC also took the privilege of felicitating Drug Formulation 2016 Organizing Committee, Keynote Speakers, and Chair whose support made conference a great success.

With the enormous feedback from the participants and supporters of Drug Formulation 2016, we are glad to announce 9th Annual Congress on Drug Formulation and Drug Design during October 19-21, 2017 Seoul, South Korea.


Past Reports  Gallery  



Click here to submit abstract to any of the above topics

sponsor

Want to Differentiate your company from your competitors and broaden your competitive edge?

Use our global platform of 3000+ Global Events

  • 25 Million+ Visitors to our Global website (conferenceseries.com)
  • 20000+ Unique Visitors per conference
  • 60000+ Page views per conference

For customized sponsorship opportunities at our conferences, or to place an ad on our websites, contact at sponsors@conferenceseries.com or call at: +1-650-268-9744

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date October 19-21, 2017
Sponsors & Exhibitors Click here for Sponsorship Opportunities
Speaker Opportunity
Poster Opportunity Available

Media Partners

Conferenceseries Destinations